All In Biotech

Drug Trial Radar · NCT00034372

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Last checked: Nov 19, 2026Latest source record: Dec 18, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

102

Actual

Start

Sep 2000

Primary completion

Not stated

Study completion Dec 2007

Sponsor

Lead sponsor
Unither PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 29, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart. Group 2 will receive three consecutive monthly doses, then at 12-week intervals through 2 years or until disease relapse up to a total of 9 doses. Group 3 will receive six consecutive monthly doses, then at 12-week intervals through 2 years or until disease relapse up to a total of 11 doses. The study will compare the time to disease relapse of patients who demonstrate an immune response to OvaRex MAb-B43.13 with time to disease relapse of those who do not demonstrate an immune response to OvaRex MAb-B43.13. Differences in the percentage of patients demonstrating an immune response in each dose regimen group will also be assessed.

Conditions

  • Ovarian Neoplasms

Interventions

  • oregovomabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Gynecologic Oncology Associates

    Newport Beach, California

  • Stanford University Medical Center

    Stanford, California

  • Walt Disney Memorial Cancer Institute

    Orlando, Florida

  • St. Joseph's Regional Medical Center

    South Bend, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Parker Hill Oncology & Hematology

    Boston, Massachusetts

  • Ellis Fischel Cancer Center

    Columbia, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Baptist Hospital of East Tennessee

    Knoxville, Tennessee

  • Texas Oncology, P.A.

    Dallas, Texas

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • Swedish Medical Center Tumor Institute

    Seattle, Washington

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada

  • Ottawa Regional Cancer Centre

    Ottawa, Ontario, Canada

  • Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont

    Fleurimont, Quebec, Canada

  • SMBD Jewish General Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.